Node Positive HER2 Negative Breast CancerPhase 3NCT02927249
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
A Phase 3 study testing Aspirin in people with Node Positive HER2 Negative Breast Cancer, run by Alliance for Clinical Trials in Oncology at 1,452 sites in 4 countries.
Trial summary
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and/or radiation therapy. Read more about this study
- Who is it for?
- Ages 18 to 69 years
- Conditions the study is for
- Node Positive HER2 Negative Breast Cancer
- What is being tested?
- Aspirin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3,021 participants
- Where
- 1,452 sitesin 4 countries
- Study dates
- 6 Jan 2017to 15 Feb 2023
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 69 years
- All sexes
- No healthy volunteers
- Adult, Older adult
- Histologic documentation of women or men with node positive, HER2 negative, anatomic stage II or III breast carcinoma and high risk node negative (defined as estrogen receptor [ER] and progesterone receptor [PR] negative and tumor size > 2 cm) within one year of diagnosis and free of recurrence; patients with pN1mic are eligible; if neoadjuvant therapy was received, either initial clinical stage (determined by physical and or radiologic examination) or post-operative pathologic stage can be used for eligibility purposes, with the higher stage determining eligibility; histologic documentation of node positivity is required; bilateral breast cancers are allowed, as long as both cancers are HER2 negative and at least one of the cancers meets eligibility
- Any ER/progesterone receptor (PgR) status allowed
- Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed; the last dose of chemotherapy or radiation therapy must be at least 30 days prior to study registration; concurrent hormonal therapy will be allowed
- Regular nonsteroidal anti-inflammatory drug (NSAID)/aspirin use at any dose (including baby aspirin) (defined as >= 5 days per week) is allowed if aspirin and/or NSAIDs are stopped for 30 days prior to study entry and throughout the study period; participants will be encouraged to use acetaminophen for minor pain and fever
- Patients must be enrolled within 1 year after diagnosis
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can be enrolled as long as the ulcers did not cause bleeding requiring a blood transfusion/major intervention; for patients who are Helicobacter pylori positive, a course of Helicobacter pylori eradication treatment must have been completed
- No history of gastrointestinal bleeding (GI) bleeding requiring a blood transfusion, endoscopic or operative intervention
- No history of any prior stroke (hemorrhagic or ischemic)
- No concurrent anticoagulation with warfarin or heparin/heparin analogues, clopidogrel, oral direct thrombin inhibitors, or direct factor XA inhibitors
- No history of atrial fibrillation or myocardial infarction
- No history of grade 4 hypertension, defined as hypertension resulting in life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis)
- No chronic (duration > 30 days) daily use of oral steroids
- No known allergy to aspirin
- No prior malignancy of any type (including ductal breast carcinoma in situ [DCIS]) within the past 5 years except for current diagnosis of breast cancer, and any prior diagnosis of basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; patients with a prior history of breast cancer greater than 5 years from study screening may participate in this study
- Concurrent enrollment on a non-chemotherapy treatment trial will be allowed, as long as that trial allows concurrent daily aspirin use
Trial locations and contacts
1,452 sites in 4 countries.
326 sites in 4 countries
United States300 sites
Hawaii Cancer Care - Savio
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
Queen's Cancer Center - Pearlridge
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Hendrick Medical Center
Abilene, Texas, 79601
Hickman Cancer Center
Adrian, Michigan, 49221
Riverwood Healthcare Center
Aitkin, Minnesota, 56431
Summa Health System - Akron Campus
Akron, Ohio, 44304
Cleveland Clinic Akron General
Akron, Ohio, 44307
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, 56007
Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico, 87102
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87102
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
Christus Saint Frances Cabrini Hospital
Alexandria, Louisiana, 71301
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Aultman Alliance Community Hospital
Alliance, Ohio, 44601
AdventHealth Altamonte
Altamonte Springs, Florida, 32701
American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah, 84003
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic PC - Ames
Ames, Iowa, 50010
Community Hospital of Anaconda
Anaconda, Montana, 59711
Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Kaiser Permanente-Anaheim
Anaheim, California, 92806
Anchorage Associates in Radiation Medicine
Anchorage, Alaska, 98508
Anchorage Radiation Therapy Center
Anchorage, Alaska, 99504
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
Saint Vincent Anderson Regional Hospital/Cancer Center
Anderson, Indiana, 46016
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
ThedaCare Regional Medical Center - Appleton
Appleton, Wisconsin, 54911
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California, 93420
PCR Oncology
Arroyo Grande, California, 93420
Randolph Hospital
Asheboro, North Carolina, 27203
AdventHealth Infusion Center Asheville
Asheville, North Carolina, 28803
King's Daughter's Medical Center
Ashland, Kentucky, 41101
Duluth Clinic Ashland
Ashland, Wisconsin, 54806
Northwest Wisconsin Cancer Center
Ashland, Wisconsin, 54806
University Cancer and Blood Center LLC
Athens, Georgia, 30607
Grady Health System
Atlanta, Georgia, 30303
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Piedmont Hospital
Atlanta, Georgia, 30309
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Kaiser Permanente-Glenlake Medical Center
Atlanta, Georgia, 30328
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342
Northside Hospital
Atlanta, Georgia, 30342
Sutter Auburn Faith Hospital
Auburn, California, 95602
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Hematology Oncology Associates of Central New York-Auburn
Auburn, New York, 13021
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Augusta Oncology Associates PC-D'Antignac
Augusta, Georgia, 30901
Augusta Oncology Associates PC-Wheeler
Augusta, Georgia, 30909
Augusta University Medical Center
Augusta, Georgia, 30912
Harold Alfond Center for Cancer Care
Augusta, Maine, 04330
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
University of Colorado Hospital
Aurora, Colorado, 80045
Rush - Copley Medical Center
Aurora, Illinois, 60504
Austin Cancer Centers-Central Austin
Austin, Texas, 78702
Austin Cancer Centers-Saint David's
Austin, Texas, 78705
Austin Cancer Centers-Northwest
Austin, Texas, 78759
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida, 33180
IU Health West Hospital
Avon, Indiana, 46123
Virginia Mason Bainbridge Island Medical Center
Bainbridge Island, Washington, 98110
Saint Alphonsus Medical Center-Baker City
Baker City, Oregon, 97814
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California, 93301
Kaiser Permanente-Baldwin Park
Baldwin Park, California, 91706
Saint Louis Cancer and Breast Institute-Ballwin
Ballwin, Missouri, 63011
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
Baltimore, Maryland, 21237
MedStar Good Samaritan Hospital
Baltimore, Maryland, 21239
Kaiser Permanente-Woodlawn Medical Center
Baltimore, Maryland, 21244
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Eastern Maine Medical Center
Bangor, Maine, 04401
Summa Health System - Barberton Campus
Barberton, Ohio, 44203
Flaget Memorial Hospital
Bardstown, Kentucky, 40004
LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana, 70805
Baton Rouge General Medical Center
Baton Rouge, Louisiana, 70806
Hematology/Oncology Clinic PLLC
Baton Rouge, Louisiana, 70809
Louisiana Hematology Oncology Associates LLC
Baton Rouge, Louisiana, 70809
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Ochsner Health Center-Summa
Baton Rouge, Louisiana, 70809
Our Lady of the Lake Physicians Group - Medical Oncology
Baton Rouge, Louisiana, 70809
Medical Center of Baton Rouge
Baton Rouge, Louisiana, 70816
Woman's Hospital
Baton Rouge, Louisiana, 70817
Ochsner High Grove
Baton Rouge, Louisiana, 70836
Bronson Battle Creek
Battle Creek, Michigan, 49017
McLaren Cancer Institute-Bay City
Bay City, Michigan, 48706
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
Beaufort Memorial Hospital
Beaufort, South Carolina, 29902
UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania, 15009
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Waldo County General Hospital
Belfast, Maine, 04915
Overlake Medical Center
Bellevue, Washington, 98004
Kaiser Permanente-Bellflower
Bellflower, California, 90706
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Gaston Hematology and Oncology Associates-Belmont
Belmont, North Carolina, 28012
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Saint Charles Health System
Bend, Oregon, 97701
Southwestern Vermont Medical Center
Bennington, Vermont, 05201
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
Mac Neal Hospital
Berwyn, Illinois, 60402
Suburban Hospital
Bethesda, Maryland, 20814
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889-5600
Saint Luke's University Hospital-Bethlehem Campus
Bethlehem, Pennsylvania, 18015
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Beverly Hospital
Beverly, Massachusetts, 01915
MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
Biddeford, Maine, 04005
Billings Clinic Cancer Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Saint Vincent Frontier Cancer Center
Billings, Montana, 59102
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
McLaren Cancer Institute-Bloomfield
Bloomfield, Michigan, 48302
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Elizabeth Boardman Hospital
Boardman, Ohio, 44512
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, 83712
Central Care Cancer Center - Bolivar
Bolivar, Missouri, 65613
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
McFarland Clinic PC-Boone
Boone, Iowa, 50036
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Essentia Health Saint Joseph's Medical Center
Brainerd, Minnesota, 56401
Cox Cancer Center Branson
Branson, Missouri, 65616
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Harrison Medical Center
Bremerton, Washington, 98310
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
Ocean Medical Center
Brick, New Jersey, 08724
United Hospital Center
Bridgeport, West Virginia, 26330
Steward Saint Elizabeth's Medical Center
Brighton, Massachusetts, 02135
IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan, 48114
Saint Joseph Mercy Brighton
Brighton, Michigan, 48114
Wellmont Bristol Regional Medical Center
Bristol, Tennessee, 37620
Wellmont Medical Associates Oncology and Hematology-Bristol
Bristol, Tennessee, 37620
Wellmont Medical Associates-Bristol
Bristol, Virginia, 24201
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin, 53045
Kings County Hospital
Brooklyn, New York, 11203
New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York, 11215
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan, 48183
Saint Joseph Regional Cancer Center
Bryan, Texas, 77802
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Roswell Park Cancer Institute
Buffalo, New York, 14263
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Highline Medical Center-Main Campus
Burien, Washington, 98166
Kaiser Permanente-Burke Medical Center
Burke, Virginia, 22015
Mills-Peninsula Medical Center
Burlingame, California, 94010
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina, 27215
University of Vermont Medical Center
Burlington, Vermont, 05401
University of Vermont and State Agricultural College
Burlington, Vermont, 05405
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Cambridge Medical Center
Cambridge, Minnesota, 55008
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Illinois CancerCare-Canton
Canton, Illinois, 61520
IHA Hematology Oncology Consultants-Canton
Canton, Michigan, 48188
Saint Joseph Mercy Canton
Canton, Michigan, 48188
Hematology and Oncology Associates Inc
Canton, Ohio, 44708
Mercy Medical Center
Canton, Ohio, 44708
Aultman Health Foundation
Canton, Ohio, 44710
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
IU Health North Hospital
Carmel, Indiana, 46032
Mercy San Juan Medical Center
Carmichael, California, 95608
Caro Cancer Center
Caro, Michigan, 48723
Carson Tahoe Regional Medical Center
Carson City, Nevada, 89703
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Rex Hematology Oncology Associates-Cary
Cary, North Carolina, 27518
Waverly Hematology Oncology
Cary, North Carolina, 27518
Eden Hospital Medical Center
Castro Valley, California, 94546
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
AdventHealth Celebration
Celebration, Florida, 34747
Rocky Mountain Cancer Centers - Centennial
Centennial, Colorado, 80112
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Miami Valley Hospital South
Centerville, Ohio, 45459
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, 19317
Chambersburg Hospital
Chambersburg, Pennsylvania, 17201
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Geauga Hospital
Chardon, Ohio, 44024
Medical University of South Carolina
Charleston, South Carolina, 29425
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Oncology Specialists of Charlotte
Charlotte, North Carolina, 28207
Southern Oncology Specialists-Charlotte
Charlotte, North Carolina, 28262
Memorial Hospital
Chattanooga, Tennessee, 37404
IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan, 48118
Saint Joseph Mercy Chelsea
Chelsea, Michigan, 48118
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
Mount Sinai Hospital Medical Center
Chicago, Illinois, 60608
University of Illinois
Chicago, Illinois, 60612
Swedish Covenant Hospital
Chicago, Illinois, 60625
Presence Resurrection Medical Center
Chicago, Illinois, 60631
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Weiss Memorial Hospital
Chicago, Illinois, 60640
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Enloe Medical Center
Chico, California, 95926
Adventist Health Cancer Care Center Chico
Chico, California, 95973
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
Oncology Hematology Care Inc-Eden Park
Cincinnati, Ohio, 45202
Oncology Hematology Care Inc-Mercy West
Cincinnati, Ohio, 45211
The Christ Hospital
Cincinnati, Ohio, 45219
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, 45220
Oncology Hematology Care Inc-Anderson
Cincinnati, Ohio, 45230
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Bethesda North Hospital
Cincinnati, Ohio, 45242
Oncology Hematology Care Inc-Blue Ash
Cincinnati, Ohio, 45242
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, 45247
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, 45255
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, 97015
Hematology Oncology Consultants-Clarkston
Clarkston, Michigan, 48346
McLaren Cancer Institute-Clarkston
Clarkston, Michigan, 48346
Newland Medical Associates-Clarkston
Clarkston, Michigan, 48346
Morton Plant Hospital
Clearwater, Florida, 33756
Wake Forest University at Clemmons
Clemmons, North Carolina, 27012
Case Western Reserve University
Cleveland, Ohio, 44106
MetroHealth Medical Center
Cleveland, Ohio, 44109
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
Prisma Health Cancer Institute - Laurens
Clinton, South Carolina, 29325
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan, 48038
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
Community Cancer Institute
Clovis, California, 93611
University Oncology Associates
Clovis, California, 93611
AdventHealth Infusion Center Haywood
Clyde, North Carolina, 28721
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Medical Center
Coeur d'Alene, Idaho, 83814
Coffeyville Regional Medical Center
Coffeyville, Kansas, 67337
Main Line Health Center-Collegeville
Collegeville, Pennsylvania, 19426
Integrity Oncology PLLC-Collierville
Collierville, Tennessee, 38017
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909
University of Missouri - Ellis Fischel
Columbia, Missouri, 65212
John B Amos Cancer Center
Columbus, Georgia, 31904
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi, 39705
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Mount Carmel East Hospital
Columbus, Ohio, 43213
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Riverside Methodist Hospital
Columbus, Ohio, 43214
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Doctors Hospital
Columbus, Ohio, 43228
New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire, 03301
MD Anderson in The Woodlands
Conroe, Texas, 77384
Cookeville Regional Medical Center
Cookeville, Tennessee, 38501
Mercy Hospital
Coon Rapids, Minnesota, 55433
Mary Imogene Bassett Hospital
Cooperstown, New York, 13326
Bay Area Hospital
Coos Bay, Oregon, 97420
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146
Baptist Health Corbin
Corbin, Kentucky, 40701
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, 40701
City of Hope Corona
Corona, California, 92879
Good Samaritan Hospital
Corvallis, Oregon, 97330
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, 92627
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Northshore Oncology Associates-Covington
Covington, Louisiana, 70433
Greater Regional Medical Center
Creston, Iowa, 50801
Oncology Hematology Care Inc-Crestview
Crestview Hills, Kentucky, 41017
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
Aurora Saint Luke's South Shore
Cudahy, Wisconsin, 53110
Northside Hospital-Forsyth
Cumming, Georgia, 30041
Mass General/North Shore Cancer Center
Danvers, Massachusetts, 01923
Carle on Vermilion
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Danville Regional Medical Center
Danville, Virginia, 24541
Southern Cancer Center PC-Daphne
Daphne, Alabama, 36526
Mercy Fitzgerald Hospital
Darby, Pennsylvania, 19023-1291
Canada13 sites
Cambridge Memorial Hospital
Cambridge, Ontario, N1R 3G2
PEI Cancer Treatment Centre-Queen Elizabeth Hospital
Charlottetown, Prince Edward Island, C1A 8T5
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7
Grand River Regional Cancer Centre at Grand River Hospital
Kitchener, Ontario, N2G 1G3
London Regional Cancer Program
London, Ontario, N6A 4L6
The Vitalite Health Network - Dr Leon Richard Oncology Centre
Moncton, New Brunswick, E1C 8X3
CIUSSSEMTL-Hopital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Atlantic Health Sciences Corporation-Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
Puerto Rico12 sites
Advance Oncology Center
Aguadilla, 00603
Doctor's Cancer Center-Arecibo
Arecibo, 00614
Cancer Center-Metro Medical Center Bayamon
Bayamón, 00959-5060
Hematologia Oncologia San Pablo
Bayamón, 00961
HIMA San Pablo Oncologic Hospital
Caguas, 00726
Doctors Cancer Center
Manati, 00674
Instituto Oncologia Moderna Ponce
Ponce, 00716
San Juan Community Oncology Group
San Juan, 00917
Primary Care Physician Group
San Juan, 00920
Centro Comprensivo de Cancer de UPR
San Juan, 00927
San Juan City Hospital
San Juan, 00936
Centro de Hematologia y Oncologia del Sur
Santa Isabel, 00757
About this study
Official title: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.
Read the detailed description
This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs ≥ 30 kg/m2) and stage (Stage II vs III).
The primary objective of this trial is to compare the effect of aspirin versus placebo upon invasive disease free survival (iDFS).
Primary objective To compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients.
Secondary objectives
- To compare the effect of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients upon:
- Distant disease-free survival
- Overall survival
- Cardiovascular disease (see Section11.3)
- To compare the toxicity of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients.
- To assess adherence to aspirin and placebo among early stage node-positive HER2 negative breast cancer patients.
- To bank tumor and germline deoxyribonucleic acid (DNA), plasma and urine collected at baseline and sequential plasma and urine collected 2 years later for future measurement of inflammatory markers.
- To determine if there are subgroups of participants characterized by lifestyle factors associates with greater inflammation for whom there is greater benefit of aspirin versus placebo upon iDFS.
Patients are followed up to 10 years after study enrollment.
- Being tested
- Placebo, Aspirin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboOther
Given PO
AspirinDrug
Given PO
| Study group | Role | What they receive |
|---|---|---|
| Arm I (aspirin) | Experimental | Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity. Receives: Drug: Aspirin |
| Arm II (Placebo) | Placebo comparator | Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Median Invasive Disease-free Survival (iDFS)
Invasive disease-free survival (iDFS), is defined as time from randomization to the first occurrence of any one of the following events for invasive disease: Distant recurrence, locoregional recurrence, ipsilateral or contralateral breast cancer, second primary (non-breast) invasive cancer or death from any cause. Censoring will occur on the date the patient was last known to be alive and free from all invasive breast cancer and second invasive primaries.
Measured: 5 years
Secondary outcomes (4)
Median Overall Survival (OS)
Overall survival (OS) is defined as the time from randomization to death from any cause; surviving patients will be censored at the date last known to be alive.
Measured: 5 years
Median Distant Disease Free Survival (DDFS)
DDFS is defined as the time from randomization to the first occurrence of any one of the following events for invasive disease: Distant recurrence, second primary (non-breast) invasive cancer or death from any cause; censoring will occur at the date the patient was last known to be alive and free from distant invasive breast cancer and second invasive primaries.
Measured: 5 years
Incidence of Cardiovascular Disease (Including Cerebrovascular Events, Myocardial Infarction, or Coronary Artery Disease Requiring Stent Placement, Angioplasty, or Bypass Surgery)
The count of patients with cardiovascular disease by arm.
Measured: 5 years
Incidence of Toxicities, Graded Using the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.3
The count of patients that experianced at least one grade 3 or higher adverse event, regardless of the attribution to study drug.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2016 (estimated)
- Study start6 Jan 2017
- Primary completion13 Dec 2021
- Study completion15 Feb 2023
Why it stopped: DSMB review
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Node Positive HER2 Negative Breast CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 3,021 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), United States Department of Defense, Bayer, Canadian Cancer Trials Group
- Responsible party
- Sponsor
- Investigators
- Wendy Chen, M.D., MPH, Study chair, Dana-Farber Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02927249
- Sponsor's protocol ID
- A011502
- Other IDs
- NCI-2016-00233, U10CA180821-01
- Status last verified
- Aug 2026
- First submitted
- 5 Oct 2016
- Last updated
- 4 Sep 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive
Publications
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM, Irvin WJ, Symington B, Visvanathan K, Pohlmann PR, Openshaw TH, Weiss A, Winer EP, Carey LA, Holmes MD. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA. 2024 May 28;331(20):1714-1721. doi: 10.1001/jama.2024.4840.
PubMed 38683596Iyer HS, James P, Valeri L, Bajunirwe F, Nankya-Mutyoba J, Njelekela M, Chiwanga F, Sewram V, Ajayi I, Adebamowo C, Dalal S, Reid TG, Rebbeck TR, Adami HO, Holmes MD. Neighborhood greenness and burden of non-communicable diseases in Sub-Saharan Africa: A multi-country cross-sectional study. Environ Res. 2021 May;196:110397. doi: 10.1016/j.envres.2020.110397. Epub 2020 Oct 31.
PubMed 33130166
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
- ClinicalTrials.gov ID
- NCT02927249
- Acronym / sponsor ID
- A011502
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: DSMB review
- Enrolment
- 3,021 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), United States Department of Defense, Bayer, Canadian Cancer Trials Group
- Study start
- 6 Jan 2017 (actual)
- Primary completion
- 13 Dec 2021 (actual)
- Study completion
- 15 Feb 2023 (actual)
- First posted
- 7 Oct 2016 (estimated)
- Results
- Posted 27 Mar 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.
Detailed description
This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs ≥ 30 kg/m2) and stage (Stage II vs III).
The primary objective of this trial is to compare the effect of aspirin versus placebo upon invasive disease free survival (iDFS).
Primary objective To compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients.
Secondary objectives
- To compare the effect of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients upon:
- Distant disease-free survival
- Overall survival
- Cardiovascular disease (see Section11.3)
- To compare the toxicity of aspirin versus placebo in early stage node-positive HER2 negative breast cancer patients.
- To assess adherence to aspirin and placebo among early stage node-positive HER2 negative breast cancer patients.
- To bank tumor and germline deoxyribonucleic acid (DNA), plasma and urine collected at baseline and sequential plasma and urine collected 2 years later for future measurement of inflammatory markers.
- To determine if there are subgroups of participants characterized by lifestyle factors associates with greater inflammation for whom there is greater benefit of aspirin versus placebo upon iDFS.
Patients are followed up to 10 years after study enrollment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I (aspirin) | Experimental | Drug: AspirinPatients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity. |
| Arm II (Placebo) | Placebo comparator | Other: PlaceboPatients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity. |
Who may qualify
- Ages
- 18 to 69 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboGiven PO | Other | Arm II (Placebo) |
| AspirinGiven PO | Drug | Arm I (aspirin) |
Primary outcome
Median Invasive Disease-free Survival (iDFS)
Time frame: 5 years
Invasive disease-free survival (iDFS), is defined as time from randomization to the first occurrence of any one of the following events for invasive disease: Distant recurrence, locoregional recurrence, ipsilateral or contralateral breast cancer, second primary (non-breast) invasive cancer or death from any cause. Censoring will occur on the date the patient was last known to be alive and free from all invasive breast cancer and second invasive primaries.
4 secondary outcomes
Median Overall Survival (OS)
Time frame: 5 years
Median Distant Disease Free Survival (DDFS)
Time frame: 5 years
Incidence of Cardiovascular Disease (Including Cerebrovascular Events, Myocardial Infarction, or Coronary Artery Disease Requiring Stent Placement, Angioplasty, or Bypass Surgery)
Time frame: 5 years
Incidence of Toxicities, Graded Using the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4.3
Time frame: 5 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38683596Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM, Irvin WJ, Symington B, Visvanathan K, Pohlmann PR, Openshaw TH, Weiss A, Winer EP, Carey LA, Holmes MD. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA. 2024 May 28;331(20):1714-1721. doi: 10.1001/jama.2024.4840.
- Derived from this study: PubMed 33130166Iyer HS, James P, Valeri L, Bajunirwe F, Nankya-Mutyoba J, Njelekela M, Chiwanga F, Sewram V, Ajayi I, Adebamowo C, Dalal S, Reid TG, Rebbeck TR, Adami HO, Holmes MD. Neighborhood greenness and burden of non-communicable diseases in Sub-Saharan Africa: A multi-country cross-sectional study. Environ Res. 2021 May;196:110397. doi: 10.1016/j.envres.2020.110397. Epub 2020 Oct 31.
- Individual participant dataSharing planned: Yes. Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive
Related trials for Node Positive HER2 Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Recruiting
Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
RecruitingPhase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
RecruitingObservational study
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization
Early-stage HER2+ Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wendy Chen, M.D., MPH study chair
Dana-Farber Cancer Institute
1,452 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Aspirin in people with Node Positive HER2 Negative Breast Cancer, run by Alliance for Clinical Trials in Oncology at 1,452 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1,452 sites in United States, Canada, Puerto Rico, Guam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Mar 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Median Invasive Disease-free Survival (iDFS) (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02927249, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.